bluuebunny/crossref_metadata_2025_split huggingface dataset:
10168-BOT-2 ANTITUMOR AROMA THERAPY WITH LEMONGRASS ESSENTIAL OIL FOR GLIOBLASTOMA
Authors: Saito Norihiko , Hirai Nozomi , Koyahara Yuki , Sato Sho , Hiramoto Yu , Fujita Satoshi , Nakayama Haruo , Hayashi Morito , Sakurai Takatoshi , Iwabuchi Satoshi 
Published: December 2023

Abstract
Aromatic essential oils have been used in cancer treatment to enhance immunity, induce sedation, and reduce the side effects of chemotherapy. Recently, essential oils have been reported to have anti-tumor effects. We have been investigating anti-tumor aroma of essential oils as a novel treatment for glioblastoma and have found that hiba essential oil has a proliferation inhibitory effect. In this study, we investigated the antitumor effect of lemongrass essential oil for glioblastoma and its antitumor aromatherapy. Human glioblastoma cells (U87, T98G) and mouse brain tumor cells (RSV-M) were used. Lemongrass essential oil was added to each tumor cell line, and growth inhibition was observed in all cell lines. In addition, lemon grass essential oil showed growth inhibition effect when the tumor cells were separated from the oil, as was the case with direct administration, suggesting that the lemongrass essential oil components that evaporated acted on tumor cells in the surrounding area. The antitumor component of lemongrass essential oil was isolated and identified as citral, an antitumor factor, by gas chromatography. Analysis of the effects of citral showed that it strongly inhibited MARK4 activity and growth in three cell lines. The mechanism revealed that citral decreased the phosphorylation of Tau protein. MARK4 is highly expressed in glioblastoma and has been reported to be involved in cell proliferation. This study suggests a potential mechanism for citral to inhibit tumor cell proliferation via MARK4 in malignant gliomas. Citral is a volatile monoterpene and may exert its antitumor effect by evaporation diffusion. Lemongrass essential oil contains citral, which shows antitumor effects, and is expected to be applied to a new glioblastoma therapy using "aroma".
10170-GMC-14 CRANIOPHARYNGIOMA REFRACTORY TO SURGERY AND RADIOSURGERY SUCCESSFULLY TREATED WITH ENCORAFENIB AND BINIMETINIB: A CASE REPORT
Authors: Tanaka Shota , Takayanagi Shunsaku , Kage Hidenori , Oda Katsutoshi , Yamada Shozo , Takami Hirokazu , Saito Nobuhito 
Published: December 2023

Abstract
Craniopharyngioma is prone to recurrence despite aggressive surgery; repeated surgery and radiotherapy are associated with risks of pituitary insufficiency, visual inacuity and anopsia, and neurocognitive dysfunction, adversely affecting patients' activity of daily life and quality of life. In a recent clinical trial in the US, molecular targeted therapy with vemurafenib and cobimetinib has achieved excellent objective response rate in BRAF-mutant cranopharyngioma. We report a case of BRAF-mutant papillary craniopharyngioma refractory to multiple surgeries and radiosurgery that was successfully treated with encorafenib and binimetinib. Molecular targeted therapy with BRAF inhibitor and MEK inhibitor can be a treatment option for BRAF-mutant craniopharyngioma, even after multiple recurrences with surgeries and radiotherapy.
10172-IM-6 DEVELOPMENT OF CAR-NK CELL THERAPY TARGETING B7H3 AGAINST GLIOBLASTOMA
Authors: Tetsuro Tachi , Kijima Noriyuki , Kuroda Hideki , Ikeda Syunya , Murakami Koki , Nakagawa Kanji , Utsugi Reina , Kawamoto Yuki , Hirayama Ryuichi , Okita Yoshiko , Kagawa Naoki , Hosen Naoki , Kishima Haruhiko 
Published: December 2023

Abstract
There is an urgent need to find new treatments for brain tumors with poor prognoses, such as glioblastoma (GBM). Recently, CAR-T cell therapy, which uses genetically engineered T cells to express chimeric antigen receptors (CAR) has been actively investigated. However, although CAR-T cell therapy has shown efficacy in preclinical GBM models, CAR-T cells have a number of limitations. When adapted for clinical use, it may exhibit undesirable side effects such as graft-versus-host disease or cytokine-releasing syndrome. Furthermore, generating an autologous product for each patient needs time and effort and is restrictive for widespread clinical use. In contrast, cord blood-derived natural killer (NK) cells show a robust safety profile in vivo and are an attractive therapeutic option for cancer treatment. In this study, we focused on developing CAR-NK therapy against GBM and used B7H3 which has recently been studied as a tumor antigen. First, we generated CAR-T cells expressing CAR against B7H3 and confirmed their antitumor effect in vitro and in vivo. Next, we generated CAR-NK cells with similar scFV from code blood. We generated eight donors of CAR-transfected NK cells and investigated the gene transfer and cell growth rate. We tested three donors of CAR-transfected NK cells and found that one of them had robust cytolytic activity against GBM cells in vitro. Overall, this study suggests that cord blood-derived CAR-NK cells targeting B7H3 may be a promising therapy for GBM.
10177-ML-5 HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT FOR RECURRENT CNS LYMPHOMA
Authors: Mishima Kazuhiko , Tkahashi Naoki , Suzuki Tomonari , Mizuno Reina , Shirahata Mitsuaki 
Published: December 2023

Abstract

BACKGROUND
The prognosis of relapsed central nervous system lymphoma (CNSL) is poor, and effective standard treatment has not been established. The BTK inhibitor or HD-MTX-based chemotherapy is re-administered if the patient responds to HD-MTX-based therapy at initial treatment, but durable remission is difficult to achieve. Thiotepa (TT) was approved in Japan as a pre-treatment for autologous hematopoietic stem cell transplantation in malignant lymphoma, and autologous stem cell transplantation (ASCT)-assisted high-dose chemotherapy (HDC) can be performed. TBC (TT, busulfan, and cyclophosphamide) and BCNU+TT are used in Europe and the US, but treatment-related mortality (TRM) has been reported in about 10% of patients. The regimen approved in Japan is BuTT (busulfan and TT) and there is little information on its efficacy and safety in relapsed CNSL. In this study, we examined the efficacy and safety of HDC-ASCT at Saitama Medical University. Subjects: Nine patients with recurrent CNSL (primary CNSL: 6 cases, secondary CNSL: 3 cases) since May 2021, age ≤ 65 years, KPS ≥ 70, are included in this study.

METHODS
After response to induction (R)MPV regimen, peripheral blood stem cells were harvested after administration of G-CSF and plerixafol, pretreated with BuTT regimen (Bu: 3.2 mg/kg, day-8 to -5, TT: 5 mg/kg, day-4, -3), and transplanted on Day 0.

RESULTS
Adverse events of Grade 3 or higher were febrile neutropenia in 5 cases, neutropenia in 9 cases, thrombocytopenia in 9 cases, pharyngitis in 5 cases, oral candida in 1 case, pleuritis in 1case, abdominal pain in 1 case, nausea in 1 case, and sepsis 1 case, but all recovered, and no TRM was observed. Six patients with primary CNSL and two with secondary CNSL are currently alive without recurrence, and one with non-CR secondary CNSL died of progression in two months.

CONCLUSION
HDC-ASCT is an effective salvage treatment for relapsed CNSL.
10184-BT-14 CLINICAL FEATURE OF HEMISPHERIC GLIOMA WITH H3F3A, PEDIATRIC-TYPE HIGH GRADE GLIOMA, H3 K27-ALTERED, NEC AND DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT, CNS WHO GRADE 4
Authors: Nakatogawa Hirokazu , Kawaji Hiroshi , Hayashi Nobuhide , Fukai Junya , Kijima Noriyuki , Shofuda Tomoko , Yoshioka Ema , Kanematsu Daisuke , Katsuma Asako , Sumida Miho , Inenaga Chikanori , Mori Kanji , Kanemura Yonehiro 
Published: December 2023

Abstract

INTRODUCTION
Diffuse midline glioma (DMG), H3K27-altered, is a CNS WHO grade 4 glioma that usually located mainly in the brainstem, thalamus and spinal cord. However, DMG located in non-midline lesions are now described as pediatric-type high grade glioma, H3K27-altered, NEC (NDMG). On the other hand, diffuse hemispheric glioma, H3G34-mutant (DHG) located in the cerebral hemispheres, and is classified under the WHO 2021 classification. It is unknown that the differences in clinical characteristics of these hemispheric tumors with H3F3A mutations. In the present study, we report a comparative study of the clinical characteristics of two groups of NDMG and DHG.

METHODS
Among 4128 brain tumor samples collected in the Kansai Network for Molecular Diagnosis of Central Nervous System Tumors, 16 NDMG and 9 DHG cases were examined for comparison of clinical characteristics.

RESULTS
There were no differences in gender, tumor location, or pathology between NDMG and DHG. The median age was 47.3 years in NDMG and 26.2 years in DHG, and NDMG was significantly older than DHG (p=0.003). There was no significant difference in MGMT promoter methylation between NDMG and DHG (p=0.087). The Kaplan-Meier survival curve showed no significant difference, with a median survival of 495 days for NDMG and 587 days for DHG (p=0.765). There was no significant different survival rate between WHO grade 3 (n=15) and grade 4 (n=9) for pathological diagnosis.

DISCUSSION AND CONCLUSION
We compared the clinical characteristics of NDMG and DHG. There are some reports that NDMG and DHG gliomas located in non-midline lesion. Removing much tumor volume may improve the prognosis of non-midline glioma. We discuss the gliomas with H3F3A mutations located in a hemispheric lesions by literature review.
10204-NQPC-7 EFFECTIVENESS AND PROBLEM OF CONVALESCENT REHABILITATION FOR INDEPENDENT LIVING IN THEIR HOUSE OF PATIENTS WITH BRAIN TUMOR
Authors: Ideguchi Makoto , Matsutani Masao , Sakamoto Hirohiko , Kitamura Takayuki , Sato Akira , Ito Shoichi , Teshima Sawane , Ueyama Mai , Takao Yuki , Omata Akiko 
Published: December 2023

Abstract

OBJECTIVE
The goal of brain tumor (BT) treatment is to achieve independent living (IL) in the house that KPS (Karnofsky Performance Status) is 70. However, 30% of KPS after postoperative concomitant chemoradiotherapy is between 30 to 60. Therefore, it is necessary to achieve IL in these patients. We report effectiveness for improvement of KPS, achievement of IL, and influence for health-related quality of life (HR-QoL) of convalescent rehabilitation.

METHODS
138 patients with BT (average of age: 63, male/female: 76/62) who admitted in our hospital in purpose of rehabilitation, whose KPS were from 40 to 60 were enrolled from 2017. The rate of improvement (RoI) that KPS upgrade by one degree and the rate of IL (RoIL) were evaluated, and the factors to influence them were analyzed. Additionally, HR-QoL using QLQ-C30 and BN-20 on admission and discharge was evaluated.

RESULTS
While rehabilitation for KPS 50 achieved 70% of RoI and 60% of RoIL, that with KPS40 or less resulted in 40% of RoI and 18% of RoIL. Primary GBM 47cases with KPS60 achieved 83% of RoI and RoIL, and with KPS40 also achieved 27% of RoI and 17% of RoIL. Multivariate analysis revealed that MMSE≥24 contributed to RoI, and MMSE≥24 and KPS≥50 to the RoIL with statistically significance. HR-QoL survey revealed that financial and future uncertainty in patients with BT were higher than that in stroke, QoL scales tended to deteriorate during the hospital, and this tendency was particularly strong in patients with malignancy.

CONCLUSIONS
Our data revealed that rehabilitation in in patients with BT for KPS 60 or less was significantly effective to achieve IL. On the other hand, it is the issue to improve ADL in patients with KPS40 or less by effective rehabilitation and to approach the improvement of mental health.
10214-COT-24 A RARE CLINICAL CASE OF LUMBAR METASTASIS FROM GLIOSARCOMA
Authors: Kakuta Kiyohide , Asano Kenichiro , Mizukami Ai , Nomura Yu , Ueno Kota , Watanabe Ryota , Yanagiya Keita , Kinoshita Shohei , Sasaki Takao , Fujiwara Nozomi , Katagai Takeshi , Morita Takahiro , Kurose Akira , Saito Atsushi 
Published: December 2023

Abstract
Gliosarcoma (GS) is a variant of glioblastoma (GBM) and has been shown to be prone to extracranial metastasis. We report a rare case of lumbar metastasis of Gliosarcoma (GS) based on histopathological findings.37-year-old male.He underwent emergency surgery for a left frontal subcortical hemorrhage. Pathological diagnosis confirmed GS. Postoperatively, the patient underwent conventional radiation chemotherapy. Later, in conjunction with cranioplasty, the remaining lesion was additionally excised and maintenance therapy was administered for 9 months. Subsequently, a follow-up MRI revealed an intracranial disseminated lesion, although the primary site was not affected. At the same time, he had difficulty moving due to back pain, and MRI revealed extracranial metastases in the second lumbar vertebra and retroperitoneum. Lumbar biopsy confirmed the diagnosis of metastasis. Pathological findings at the initial surgery showed that the tumor consisted of GS and gemistocyte-like components, and immunostaining and genetic findings showed IDH wild type GBM. Additional tissue samples showed predominantly gemistocyte-like components and no GS component, and the genetic profile was similar.Lumbar biopsies showed predominantly GS and no gemistocyte-like components. MGMT methylation changed from methylation-negative to positive and then negative by immunostaining and MS-PCR. In a previous report, Feldheim et al. performed a meta-analysis of MGMT methylation changes in relapsing GBM and reported increased methylation after relapse. In addition, Jimenez et al. quantitatively analyzed MGMT methylation in recurrent GBM by pyrosequencing and found an increased rate of methylation in about half of the cases. These reports indicate that MGMT methylation is altered following therapeutic intervention. In the present case, it was hypothesized that an intracranial lesion that was initially unmethylated was methylated by the intervention, but an unmethylated, treatment-resistant GS component metastasized to the extracranial space. The clinical course of this case was a rare example of evidence of a change in MGMT methylation due to therapeutic intervention.
10215-ML-7 CLINICAL OUTCOME OF TIRABRUTINIB IN PCNSL REFRACTORY TO R-MPV THERAPY
Authors: Ohka Fumiharu , Yamaguchi Junya , Motomura Kazuya , Kibe Yuji , Nishikawa Tomohide , Maeda Sachi , Shimizu Hiroki , Takido Yuhei , Saito Ryuta 
Published: December 2023

Abstract
In recent years, R-MPV therapy has been widely used for treatment of primary central nervous system lymphoma (PCNSL). Although a high response rate and favorable prognosis have been reported with R-MPV therapy using multiple drugs, the treatment strategy for cases refractory to induction therapy has not been established. High-dose radiotherapy is currently recommended for refractory cases, however, the efficacy and frequency of adverse events such as leukoencephalopathy are not yet clear. Tirabrutinib has been available for recurrent or refractory PCNSL cases since 2020. However, there have been few reports on the results of tilabrutinib in these refractory cases. We have been using tirabrutinib for these refractory cases since its introduction. Here, we compared the results of tirabrutinib with those before the introduction of tirabrutinib. We investigated 30 cases with PCNSL treated with R-MPV at our hospital since 2013. 5 (16.7%) of the 30 cases revealed refractory to R-MPV. Two cases were promptly treated with irradiation (total 40-45 Gy) and both remitted, but one (a 70's male) had extensive white matter changes. One case (40's female) also had white matter changes but maintained CR for 4 years and 8 months. All three patients treated with tirabrutinib achieved CR or PR immediately, and two patients (a 60's woman and a 70's man) received whole brain irradiation of 23.4 Gy at 26 and 28 days after tirabrutinib introduction and remained in remission for 2 years 3 months and 2 years 4 months respectively with no significant white matter changes. The results suggest that tirabrutinib may be useful for cases refractory to R-MPV therapy. Because the long-term results of tirabrutinib are not yet clear, careful consideration should be given to the necessity of radiotherapy for cases who have achieved remission with tirabrutinib.
10220-NI-9 PREDICTION OF AN EFFECT OF ELIMINATING HIGH INTENSITY AREAS ON FLAIR IMAGING AFTER ONE-SHOT BEVACIZUMAB FOR GLIOBLASTOMA
Authors: Beppu Takaaki , Sato Yuichi , Fujiwara Shunrou , Ogasawara Kuniaki 
Published: December 2023

Abstract

PURPOSE
Bevacizumab (BEV) demonstrates an affect of alleviating high intensity areas (HIA) on FLAIR imaging in glioblastoma, although it shows differences between patients. We investigated prediction factors of alleviating HIA after one-shot BEV.

METHODS
Twenty patients with glioblastoma enrolled in this study. MRI including arterial spin labeling (ASL) were performed before and after administrating BEV (one-shot at 10 mg/kg). From eliminating volume of HIA on FLAIR between before and after BEV, we assessed the eliminating rates (1-pre-volume/post-volume%). All patients were divided into two groups, either less or more than the mean of the eliminating rate. We compared results of plausible factors before BEV, including HIA volume, enhancing volume on T1WI with contrast media, tumor locations, presence of central necrosis, and CBF T/N on ASL, between two groups.

RESULTS
The mean of the eliminating rate of HIA volume on FLAIR between before and after BEV was 40.7%. Between two groups less than and more than eliminating rate of 40.7%. only CBF T/N at a large region of interest surrounding entire tumor showed a significant difference, which patients with larger eliminating rate showed smaller CBF T/N.

CONCLUSION
The results in this study suggested a possibility that CBF T/N on ASL is a predction factor of alleviating HIA after one-shot BEV. CBF T/N on ASL has been reported to correlates to the amount of expression of VEGF. In patients with smaller CBF T/N, the VEGF-neutralizing effect from one-shot BEV is likely to be relatively high.
10236-NI-11 IMAGING FEATURES AND CONSIDERATION OF PROGRESSION PATTERN OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Authors: Yuji Kibe , Ohka Fumiharu , Motomura Kazuya , Yamaguchi Junya , Nishikawa Tomohide , Maeda Sachi , Shimizu Hiroki , Takido Yuhei , Saito Ryuta 
Published: December 2023

Abstract

BACKGROUND
Diffuse hemispheric gliomas, H3 G34-mutant (DHG-G34m) are newly recognized pediatric-type diffuse high-grade gliomas. We describe detail imaging features of seven cases of DHG-G34m and consider about progression pattern of DHG-G34m.

RESULTS
H3 G34R/V was detected by sanger sequencing in all tumors. Mean age of onset was 16.5 years (range: 10-26). Tumors were located on frontal (n=2), parietal (n=2), temporal lobe (n=1) and insular cortex (n=1), respectively. In one case, gliomatosis cerebri-like multiple lesions involving the cortex and basal ganglia occurred. Magnetic resonance imaging showed T2/FLAIR high lesions with poor contrast enhancement in all cases. All tumors harbored restriction of diffusion. Strong accumulation of methionine was observed in six cases. Tumors of these cases harbored T2/FLAIR high lesions in the deep white matter which showed methionine accumulation. All patients underwent surgery (total resection in one case, partial resection in five cases, and biopsy in one case) followed by radiation chemotherapy. The mean progression free survival was 9.9 months (range: 1.6-33.1 months). All recurrent tumors harbored diffuse infiltration along the white matter adjacent to surgical cavity, which was temporarily reduced by bevacizumab, but eventually invaded into cerebral peduncle via pyramidal tract and into contralateral brain via corpus callosum or anterior commissure in six cases. Extensive infiltration of tumor cells into the contralateral brain and brain stem was confirmed in the autopsy brain of one case. The mean overall survival was 21.6 months (range: 8.9-48.3 months).

CONCLUSION
DHG-G34m showed deep white matter infiltration from the time of initial onset, which made gross total resection difficult. Residual lesions extensively infiltrated along the white matter and eventually invaded the brainstem and contralateral brain, leading to death.
10249-PEDT-8 CURRENT STATUS AND ISSUES OF PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
Authors: Suzuki Tomonari , mizuno reina , shirahata mitsuaki , adachi junihci , nishikawa ryo , fujimaki takamitsu , mishima kazuhiko 
Published: December 2023

Abstract
that predominantly occurs in childhood, with a median survival of less than one year. Herein we present a recent case of DIPG and discuss the current status and future challenges. The patient was a 7-year-old boy who complained of tinnitus, headaches, and unstable gait. The MRI showed diffuse enlargement of the pons, and the contrast-enhanced T1-weighted image exhibited an irregular ring-like enhancement. Neurologically, he presented with left abducens nerve palsy, horizontal gaze nystagmus, significant left ataxia, and truncal ataxia. As the lesion extended to the left cerebellar peduncle, a stereotactic biopsy was performed. However, postoperative bleeding occurred, resulting in transient consciousness disturbance, left facial palsy, speech disturbance, and dysphagia, necessitating enteral nutrition management. The pathological diagnosis was high-grade glioma, IDH wild type, H3K27M mutation (-), TERTp wild type, BRAF V600E mutation (-), BRAF fusion (-), and MGMT unmethylated. After surgery, the patient received radiation therapy (54Gy/30fr), and his symptoms improved, allowing him to resume oral intake. Post-irradiation, the lesion shrank, and he was discharged home without assistance. However, six months later, his symptoms worsened, and he started taking temozolomide orally, but the effect was limited. Nine months later, he became unable to take oral medication, and a central venous port was placed. We coordinated with home care physicians to provide intravenous and palliative treatments, but respiratory and consciousness disturbances gradually worsened, and he died 10 months after the initial diagnosis. The median survival of DIPG patients treated at our hospital is currently 10.5 months, and this case followed a typical course. The development of novel treatments is desired, but due to the rarity of the disease, conducting comparative trials is challenging. Hence, registry data forming a control group are necessary. Additionally, transitioning to home-based palliative care and sharing information on supportive therapies are also critical tasks.
10255-BOT-5 EXOSOMAL MIRNAS RELEASED FROM GLIOBLASTOMA CELLS AFTER BNCT TARGET CELL PROLIFERATION AND SURVIVAL SIGNALS
Authors: Natsuko Kondo , Kinouchi Tadatoshi , Sakurai Yoshinori , Suzuki Minoru , Hirata Eishu , Okada Masayasu , Natsumeda Manabu 
Published: December 2023

Abstract
Boron neutron capture therapy (BNCT) is a tumor -selective particle radiation therapy. In BNCT, p-boronophenyl alanine, which is actively taken up by tumor cells through LAT1 transporter, a member of the system L family of heterodimeric, sodium-independent, amino acid transporters, is administrated to patients, and thermal or epithermal neutron is irradiated to tumor tissue of the patients. Nuclear capture and fission reactions between boron-10 and thermal neutron occurred only in tumor cells produce high- linear energy transfer (LET) alpha particles and recoiling lithium-7 (7Li). These high LET particles have very short pathlength (5-9 μmeter), and kill boron-10 containing tumor cells sparing adjacent normal tissue cells. BNCT was applied to malignant glioma, the most devastating tumor and has prolonged the survival of malignant glioma patients. In this study, we comprehensively investigated the micro RNAs (miRNAs) in exosomes derived from BNCT-treated glioblastoma U87 MG cells using microarray. Comparing with non-treated cells, more than 300 up-regulated miRNAs or 100 down-regulated miRNAs were detected in BNCT-treated cells. From the results of the prediction analysis of the target genes which interact with the miRNAs, the pathway analysis was performed. We found significantly associated pathways, such as Focal adhesion-PI3K-Akt-mTOR, Ras, MAPK, etc. miRNAs in exosomes released from BNCT-treated glioblastoma cells may suppress such essential pathways for cell proliferation and survival.